No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Pembrolizumab plus cetuximab shows early clinical efficacy for patients with recurrent or metastatic head and neck squamous cell carcinoma

byTeddy Guo

July 15, 2021

in StudyGraphics

Reading Time: 1 min read

Click to read the study in The Lancet Oncology.

RELATED REPORTS

Pembrolizumab improves survival in locally advanced head and neck cancer

#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors

RelatedReports

Elective neck dissection may be unnecessary for adenoid cystic carcinoma

Oncology

Pembrolizumab improves survival in locally advanced head and neck cancer

August 26, 2025

StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer

July 18, 2025

StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

July 9, 2025

StudyGraphics

#VisualAbstract: Adjuvant PD-1 Blockade With Camrelizumab Improves Survival in Nasopharyngeal Carcinoma

March 26, 2025

#VisualAbstract: Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

#VisualAbstract: Systematic analysis of tobacco smoking prevalence in 204 countries from 1990 to 2019

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result